Zheng Feixia, Ye Xiaoyan, Chen Yuanyuan, Wang Hongying, Fang Shiyu, Shi Xulai, Lin Zhongdong, Lin Zhenlang
Department of Pediatrics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Pediatrics, Aksu First People's Hospital, Xinjiang, China.
Front Neurol. 2022 Aug 10;13:911784. doi: 10.3389/fneur.2022.911784. eCollection 2022.
Few studies have evaluated hyponatremia management in children with bacterial meningitis (BM). Thus, we aimed to describe variations in clinical practice, the effectiveness of sodium management, and adverse outcomes in children with BM and hyponatremia.
This retrospective cross-sectional study conducted at a tertiary institution analyzed participants' demographic, clinical, and sodium-altering treatment data. The sodium trigger for treatment was defined as pretreatment sodium level, with response and overcorrection defined as increments of ≥5 and >10 mmol/L after 24 h, respectively.
This study enrolled 364 children with BM (age: <16 years; 215 boys). Hyponatremia occurred in 62.1% of patients, among whom 25.7% received sodium-altering therapies; 91.4% of those individuals had moderate/severe hyponatremia. Monotherapy was the most common initial hyponatremia treatment. After 24 h of treatment initiation, 82.4% of the patients responded. Logistic regression analyses revealed that ΔNa <5 mmol/L [odds ratio (OR) 15.52, 95% CI 1.71-141.06, = 0.015] and minimum Glasgow Coma Scale (GCS) score ≤ 8 (OR 11.09, 95% CI 1.16-105.73, = 0.036) predicted dysnatremia at 48 h after treatment initiation. Although rare, persistent moderate/severe hyponatremia or hypernatremia at 48 h after treatment initiation was associated with a high mortality rate (57.1%).
This study found that most cases of hyponatremia responded well to various treatments. It is important to identify and institute appropriate treatment early for moderate or severe hyponatremia or hypernatremia in children with BM. This study was limited by its non-randomized nature.
很少有研究评估细菌性脑膜炎(BM)患儿的低钠血症管理情况。因此,我们旨在描述临床实践中的差异、钠管理的有效性以及BM合并低钠血症患儿的不良结局。
这项在一家三级医疗机构进行的回顾性横断面研究分析了参与者的人口统计学、临床和钠改变治疗数据。治疗的钠触发点定义为治疗前钠水平,反应和纠正过度分别定义为24小时后钠水平升高≥5和>10 mmol/L。
本研究纳入了364例BM患儿(年龄:<16岁;215例男孩)。62.1%的患者发生了低钠血症,其中25.7%接受了钠改变治疗;这些患者中91.4%为中度/重度低钠血症。单一疗法是最常见的初始低钠血症治疗方法。开始治疗24小时后,82.4%的患者有反应。逻辑回归分析显示,ΔNa<5 mmol/L[比值比(OR)15.52,95%置信区间1.71-141.06,P=0.015]和最低格拉斯哥昏迷量表(GCS)评分≤8(OR 11.09,95%置信区间1.16-105.73,P=0.036)预测开始治疗48小时后发生钠代谢紊乱。虽然罕见,但开始治疗48小时后持续存在的中度/重度低钠血症或高钠血症与高死亡率(57.1%)相关。
本研究发现,大多数低钠血症病例对各种治疗反应良好。对于BM患儿的中度或重度低钠血症或高钠血症,早期识别并采取适当治疗很重要。本研究受其非随机性质的限制。